Neutralizing antibody and T-cell responses against SARS-CoV-2 variants by heterologous CoronaVac/ChAdOx-1 vaccination in elderly subjects with chronic obstructive pulmonary disease
Data on humoral and cellular immune responses against SARS-CoV-2 after receiving heterologous CoronaVac/ChAdOx-1 (CoVac/ChAd) vaccination in subjects with chronic obstructive pulmonary disease (COPD) are still limited. Therefore, we determined the neutralizing antibody (NAb) and T-cell responses aga...
Saved in:
| Published in | Vaccine Vol. 41; no. 40; pp. 5901 - 5909 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Kidlington
Elsevier Ltd
15.09.2023
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0264-410X 1873-2518 1873-2518 |
| DOI | 10.1016/j.vaccine.2023.08.034 |
Cover
Loading…
| Abstract | Data on humoral and cellular immune responses against SARS-CoV-2 after receiving heterologous CoronaVac/ChAdOx-1 (CoVac/ChAd) vaccination in subjects with chronic obstructive pulmonary disease (COPD) are still limited. Therefore, we determined the neutralizing antibody (NAb) and T-cell responses against SARS-CoV-2 wild type (WT) and variants of concern (VOCs) in COPD patients.
The levels of NAb as well as specific CD4 and CD8 T-cell responses against SARS-CoV-2 WT and VOCs were determined in COPD patients before and after vaccination.
Four weeks after vaccinations, the median levels of % inhibition of NAb against SARS-CoV-2 WT, Alpha, Beta, and Delta variants were significantly higher compared to pre-vaccination. The induction of NAb against Omicron was very low compared to other variants. At four weeks after vaccination, in comparison to pre-vaccination, the increasing trend of TNF-α-, IFN-γ-, IL-4-, IL-17-, IL-10-, and FasL-producing CD4 T-cells upon stimulation with WT spike peptides were demonstrated. No difference in T-cell responses to spike peptides of Alpha, Beta, and Delta variants and their WT homologs was observed.
Heterologous CoVac/ChAd vaccine induced the production of NAb against SARS-CoV-2 WT, Alpha, Beta, and Delta variants, but low for Omicron in COPD patients. Induction of CD4 T-cell subset responses was slightly observed by this vaccine regimen.
Clinical Trials Registry: This study was approved by the Clinical Trials Registry (Study ID: TCTR20210822002). |
|---|---|
| AbstractList | AbstractBackgroundData on humoral and cellular immune responses against SARS-CoV-2 after receiving heterologous CoronaVac/ChAdOx-1 (CoVac/ChAd) vaccination in subjects with chronic obstructive pulmonary disease (COPD) are still limited. Therefore, we determined the neutralizing antibody (NAb) and T-cell responses against SARS-CoV-2 wild type (WT) and variants of concern (VOCs) in COPD patients. MethodsThe levels of NAb as well as specific CD4 and CD8 T-cell responses against SARS-CoV-2 WT and VOCs were determined in COPD patients before and after vaccination. ResultsFour weeks after vaccinations, the median levels of % inhibition of NAb against SARS-CoV-2 WT, Alpha, Beta, and Delta variants were significantly higher compared to pre-vaccination. The induction of NAb against Omicron was very low compared to other variants. At four weeks after vaccination, in comparison to pre-vaccination, the increasing trend of TNF-α-, IFN-γ-, IL-4-, IL-17-, IL-10-, and FasL-producing CD4 T-cells upon stimulation with WT spike peptides were demonstrated. No difference in T-cell responses to spike peptides of Alpha, Beta, and Delta variants and their WT homologs was observed. ConclusionHeterologous CoVac/ChAd vaccine induced the production of NAb against SARS-CoV-2 WT, Alpha, Beta, and Delta variants, but low for Omicron in COPD patients. Induction of CD4 T-cell subset responses was slightly observed by this vaccine regimen. Clinical Trials Registry: This study was approved by the Clinical Trials Registry (Study ID: TCTR20210822002). Data on humoral and cellular immune responses against SARS-CoV-2 after receiving heterologous CoronaVac/ChAdOx-1 (CoVac/ChAd) vaccination in subjects with chronic obstructive pulmonary disease (COPD) are still limited. Therefore, we determined the neutralizing antibody (NAb) and T-cell responses against SARS-CoV-2 wild type (WT) and variants of concern (VOCs) in COPD patients. The levels of NAb as well as specific CD4 and CD8 T-cell responses against SARS-CoV-2 WT and VOCs were determined in COPD patients before and after vaccination. Four weeks after vaccinations, the median levels of % inhibition of NAb against SARS-CoV-2 WT, Alpha, Beta, and Delta variants were significantly higher compared to pre-vaccination. The induction of NAb against Omicron was very low compared to other variants. At four weeks after vaccination, in comparison to pre-vaccination, the increasing trend of TNF-α-, IFN-γ-, IL-4-, IL-17-, IL-10-, and FasL-producing CD4 T-cells upon stimulation with WT spike peptides were demonstrated. No difference in T-cell responses to spike peptides of Alpha, Beta, and Delta variants and their WT homologs was observed. Heterologous CoVac/ChAd vaccine induced the production of NAb against SARS-CoV-2 WT, Alpha, Beta, and Delta variants, but low for Omicron in COPD patients. Induction of CD4 T-cell subset responses was slightly observed by this vaccine regimen. Data on humoral and cellular immune responses against SARS-CoV-2 after receiving heterologous CoronaVac/ChAdOx-1 (CoVac/ChAd) vaccination in subjects with chronic obstructive pulmonary disease (COPD) are still limited. Therefore, we determined the neutralizing antibody (NAb) and T-cell responses against SARS-CoV-2 wild type (WT) and variants of concern (VOCs) in COPD patients.BACKGROUNDData on humoral and cellular immune responses against SARS-CoV-2 after receiving heterologous CoronaVac/ChAdOx-1 (CoVac/ChAd) vaccination in subjects with chronic obstructive pulmonary disease (COPD) are still limited. Therefore, we determined the neutralizing antibody (NAb) and T-cell responses against SARS-CoV-2 wild type (WT) and variants of concern (VOCs) in COPD patients.The levels of NAb as well as specific CD4 and CD8 T-cell responses against SARS-CoV-2 WT and VOCs were determined in COPD patients before and after vaccination.METHODSThe levels of NAb as well as specific CD4 and CD8 T-cell responses against SARS-CoV-2 WT and VOCs were determined in COPD patients before and after vaccination.Four weeks after vaccinations, the median levels of % inhibition of NAb against SARS-CoV-2 WT, Alpha, Beta, and Delta variants were significantly higher compared to pre-vaccination. The induction of NAb against Omicron was very low compared to other variants. At four weeks after vaccination, in comparison to pre-vaccination, the increasing trend of TNF-α-, IFN-γ-, IL-4-, IL-17-, IL-10-, and FasL-producing CD4 T-cells upon stimulation with WT spike peptides were demonstrated. No difference in T-cell responses to spike peptides of Alpha, Beta, and Delta variants and their WT homologs was observed.RESULTSFour weeks after vaccinations, the median levels of % inhibition of NAb against SARS-CoV-2 WT, Alpha, Beta, and Delta variants were significantly higher compared to pre-vaccination. The induction of NAb against Omicron was very low compared to other variants. At four weeks after vaccination, in comparison to pre-vaccination, the increasing trend of TNF-α-, IFN-γ-, IL-4-, IL-17-, IL-10-, and FasL-producing CD4 T-cells upon stimulation with WT spike peptides were demonstrated. No difference in T-cell responses to spike peptides of Alpha, Beta, and Delta variants and their WT homologs was observed.Heterologous CoVac/ChAd vaccine induced the production of NAb against SARS-CoV-2 WT, Alpha, Beta, and Delta variants, but low for Omicron in COPD patients. Induction of CD4 T-cell subset responses was slightly observed by this vaccine regimen.CONCLUSIONHeterologous CoVac/ChAd vaccine induced the production of NAb against SARS-CoV-2 WT, Alpha, Beta, and Delta variants, but low for Omicron in COPD patients. Induction of CD4 T-cell subset responses was slightly observed by this vaccine regimen.This study was approved by the Clinical Trials Registry (Study ID: TCTR20210822002).CLINICAL TRIALS REGISTRYThis study was approved by the Clinical Trials Registry (Study ID: TCTR20210822002). BackgroundData on humoral and cellular immune responses against SARS-CoV-2 after receiving heterologous CoronaVac/ChAdOx-1 (CoVac/ChAd) vaccination in subjects with chronic obstructive pulmonary disease (COPD) are still limited. Therefore, we determined the neutralizing antibody (NAb) and T-cell responses against SARS-CoV-2 wild type (WT) and variants of concern (VOCs) in COPD patients.MethodsThe levels of NAb as well as specific CD4 and CD8 T-cell responses against SARS-CoV-2 WT and VOCs were determined in COPD patients before and after vaccination.ResultsFour weeks after vaccinations, the median levels of % inhibition of NAb against SARS-CoV-2 WT, Alpha, Beta, and Delta variants were significantly higher compared to pre-vaccination. The induction of NAb against Omicron was very low compared to other variants. At four weeks after vaccination, in comparison to pre-vaccination, the increasing trend of TNF-α-, IFN-γ-, IL-4-, IL-17-, IL-10-, and FasL-producing CD4 T-cells upon stimulation with WT spike peptides were demonstrated. No difference in T-cell responses to spike peptides of Alpha, Beta, and Delta variants and their WT homologs was observed.ConclusionHeterologous CoVac/ChAd vaccine induced the production of NAb against SARS-CoV-2 WT, Alpha, Beta, and Delta variants, but low for Omicron in COPD patients. Induction of CD4 T-cell subset responses was slightly observed by this vaccine regimen.Clinical Trials Registry: This study was approved by the Clinical Trials Registry (Study ID: TCTR20210822002). Data on humoral and cellular immune responses against SARS-CoV-2 after receiving heterologous CoronaVac/ChAdOx-1 (CoVac/ChAd) vaccination in subjects with chronic obstructive pulmonary disease (COPD) are still limited. Therefore, we determined the neutralizing antibody (NAb) and T-cell responses against SARS-CoV-2 wild type (WT) and variants of concern (VOCs) in COPD patients. The levels of NAb as well as specific CD4 and CD8 T-cell responses against SARS-CoV-2 WT and VOCs were determined in COPD patients before and after vaccination. Four weeks after vaccinations, the median levels of % inhibition of NAb against SARS-CoV-2 WT, Alpha, Beta, and Delta variants were significantly higher compared to pre-vaccination. The induction of NAb against Omicron was very low compared to other variants. At four weeks after vaccination, in comparison to pre-vaccination, the increasing trend of TNF-α-, IFN-γ-, IL-4-, IL-17-, IL-10-, and FasL-producing CD4 T-cells upon stimulation with WT spike peptides were demonstrated. No difference in T-cell responses to spike peptides of Alpha, Beta, and Delta variants and their WT homologs was observed. Heterologous CoVac/ChAd vaccine induced the production of NAb against SARS-CoV-2 WT, Alpha, Beta, and Delta variants, but low for Omicron in COPD patients. Induction of CD4 T-cell subset responses was slightly observed by this vaccine regimen. Clinical Trials Registry: This study was approved by the Clinical Trials Registry (Study ID: TCTR20210822002). |
| Author | Takheaw, Nuchjira Limsukon, Atikun Duangjit, Pilaiporn Pothirat, Chaicharn Chuensirikulchai, Kantinan Laopajon, Witida Trongtrakul, Konlawij Kasinrerk, Watchara Inchai, Juthamas Tajarernmuang, Pattraporn Liwsrisakun, Chalerm Pata, Supansa Chaiwong, Warawut Theerakittikul, Theerakorn Cheyasawan, Passaworn Bumroongkit, Chaiwat Deesomchok, Athavudh Niyatiwatchanchai, Nutchanok |
| Author_xml | – sequence: 1 givenname: Warawut orcidid: 0000-0003-4459-7681 surname: Chaiwong fullname: Chaiwong, Warawut organization: Division of Pulmonary, Critical Care, and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand – sequence: 2 givenname: Nuchjira orcidid: 0000-0002-7239-9482 surname: Takheaw fullname: Takheaw, Nuchjira organization: Division of Clinical Immunology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand – sequence: 3 givenname: Supansa surname: Pata fullname: Pata, Supansa organization: Division of Clinical Immunology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand – sequence: 4 givenname: Witida surname: Laopajon fullname: Laopajon, Witida organization: Division of Clinical Immunology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand – sequence: 5 givenname: Pilaiporn surname: Duangjit fullname: Duangjit, Pilaiporn organization: Division of Pulmonary, Critical Care, and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand – sequence: 6 givenname: Juthamas surname: Inchai fullname: Inchai, Juthamas organization: Division of Pulmonary, Critical Care, and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand – sequence: 7 givenname: Chaicharn surname: Pothirat fullname: Pothirat, Chaicharn organization: Division of Pulmonary, Critical Care, and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand – sequence: 8 givenname: Chaiwat surname: Bumroongkit fullname: Bumroongkit, Chaiwat organization: Division of Pulmonary, Critical Care, and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand – sequence: 9 givenname: Athavudh orcidid: 0000-0003-1375-4541 surname: Deesomchok fullname: Deesomchok, Athavudh organization: Division of Pulmonary, Critical Care, and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand – sequence: 10 givenname: Theerakorn orcidid: 0000-0001-6182-6218 surname: Theerakittikul fullname: Theerakittikul, Theerakorn organization: Division of Pulmonary, Critical Care, and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand – sequence: 11 givenname: Atikun orcidid: 0000-0001-7995-8649 surname: Limsukon fullname: Limsukon, Atikun organization: Division of Pulmonary, Critical Care, and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand – sequence: 12 givenname: Pattraporn orcidid: 0000-0003-4409-1832 surname: Tajarernmuang fullname: Tajarernmuang, Pattraporn organization: Division of Pulmonary, Critical Care, and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand – sequence: 13 givenname: Nutchanok orcidid: 0000-0002-3081-1379 surname: Niyatiwatchanchai fullname: Niyatiwatchanchai, Nutchanok organization: Division of Pulmonary, Critical Care, and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand – sequence: 14 givenname: Konlawij orcidid: 0000-0002-2544-7322 surname: Trongtrakul fullname: Trongtrakul, Konlawij organization: Division of Pulmonary, Critical Care, and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand – sequence: 15 givenname: Kantinan surname: Chuensirikulchai fullname: Chuensirikulchai, Kantinan organization: Division of Clinical Immunology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand – sequence: 16 givenname: Passaworn surname: Cheyasawan fullname: Cheyasawan, Passaworn organization: Biomedical Technology Research Center, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency at the Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand – sequence: 17 givenname: Chalerm surname: Liwsrisakun fullname: Liwsrisakun, Chalerm email: chalerm.liw@cmu.ac.th organization: Division of Pulmonary, Critical Care, and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand – sequence: 18 givenname: Watchara surname: Kasinrerk fullname: Kasinrerk, Watchara email: Watchara.k@cmu.ac.th organization: Division of Clinical Immunology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand |
| BookMark | eNqFkl-LEzEUxQdZwW71IwgBX3yZ7k0mM5NBFErxHywu2HXxLWSSO23qNKnJTLV-Lj-gqV18WJA-JQ_nHO49v3uZXTjvMMueU5hRoNXVZrZXWluHMwasmIGYQcEfZRMq6iJnJRUX2QRYxXNO4euT7DLGDQCUBW0m2e9POA5B9faXdSui3GBbbw7pY8htrrHvScC48y5iJGqlrIsDWc4_L_OFv8sZ2atgkymS9kDWOGDwvV_5MZKFD96pO6WvFuu5ufmZU3IaUg3WO2Idwd5g6A8kju0GdYr4YYc10evks5r4Ng5h1IPdI9mN_TaFhQMxNqKK-DR73Kk-4rP7d5p9eff2dvEhv755_3Exv841L6shr-quq0tT0hqFoGhMWdSCccp5x0pojIAGuFC16lDVtdIdb9vSiAaUoiAKVkyzl6fcXfDfR4yD3Np4LEU5TEvKggEw0XDanJUyUfKCVyUtkvTFA-nGj8GlRZKqojWvmgRumr06qXTwMQbspLbD3_ISLttLCvIIX27kPXx5hC9ByAQ_ucsH7l2w21ThWd-bkw9TrXuLQereJh6q_4YHjP8GpTIyCXJ5PKvjVbECoKkqSAGv_x8gjbdnBvgD04nlQw |
| CitedBy_id | crossref_primary_10_1016_j_chest_2024_06_3789 |
| Cites_doi | 10.3390/microorganisms9081692 10.4049/jimmunol.1700420 10.1002/jmv.25889 10.1016/S0140-6736(21)01420-3 10.1183/13993003.04474-2020 10.1016/S1473-3099(21)00420-5 10.1038/s41591-021-01449-9 10.1177/20587392211066188 10.1126/science.abn7591 10.1038/s41598-021-98749-4 10.1080/21645515.2022.2029111 10.1164/rccm.201908-1590ST 10.4049/jimmunol.150.10.4303 10.1016/S0140-6736(20)32661-1 10.3390/ijms21218011 10.2147/COPD.S329783 10.1152/ajplung.00305.2021 10.1136/bmjresp-2022-001268 10.1016/S0140-6736(21)01429-X 10.1038/s41598-022-25642-z 10.1146/annurev-med-042420-113212 10.1016/S0140-6736(21)01694-9 10.1038/s41591-022-01704-7 10.1186/s12916-021-02058-6 10.1038/s41590-021-01122-w 10.1080/22221751.2021.2022440 10.1038/s41418-022-01015-x 10.1016/j.omtm.2020.05.013 10.1016/S2213-2600(21)00357-X 10.1038/s41591-022-01705-6 10.1016/j.clim.2020.108651 10.1021/acs.jcim.1c01451 10.1186/s12931-021-01755-3 10.1080/21645515.2022.2052525 10.1080/22221751.2021.2017757 10.1183/16000617.0199-2020 10.1016/j.eclinm.2021.100789 10.1016/j.ebiom.2021.103761 10.4049/jimmunol.159.11.5197 10.1183/13993003.00497-2022 10.1164/rccm.202009-3533SO 10.1371/journal.pmed.1003874 10.1186/s12979-022-00279-8 10.1016/S1473-3099(20)30987-7 10.1038/s41591-021-01464-w 10.1186/s13223-022-00719-6 |
| ContentType | Journal Article |
| Copyright | 2023 Elsevier Ltd Elsevier Ltd 2023. Elsevier Ltd Copyright © 2023 Elsevier Ltd. All rights reserved. |
| Copyright_xml | – notice: 2023 Elsevier Ltd – notice: Elsevier Ltd – notice: 2023. Elsevier Ltd – notice: Copyright © 2023 Elsevier Ltd. All rights reserved. |
| DBID | AAYXX CITATION 3V. 7QL 7RV 7T2 7T5 7U9 7X7 7XB 88C 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9- K9. KB0 LK8 M0R M0S M0T M1P M2O M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI Q9U 7X8 7S9 L.6 |
| DOI | 10.1016/j.vaccine.2023.08.034 |
| DatabaseName | CrossRef ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Health and Safety Science Abstracts (Full archive) Immunology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitle | CrossRef Research Library Prep ProQuest Central Student ProQuest Central Essentials SciTech Premium Collection Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library Health & Safety Science Abstracts ProQuest Public Health ProQuest Central Basic ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest SciTech Collection ProQuest Medical Library Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | AGRICOLA MEDLINE - Academic Research Library Prep |
| Database_xml | – sequence: 1 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Veterinary Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1873-2518 |
| EndPage | 5909 |
| ExternalDocumentID | 10_1016_j_vaccine_2023_08_034 1_s2_0_S0264410X23009660 S0264410X23009660 |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 53G 5RE 5VS 7-5 71M 7RV 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABKYH ABMAC ABMZM ABRWV ABUWG ACDAQ ACGFO ACGFS ACIEU ACIUM ACPRK ACRLP ACVFH ADBBV ADCNI ADEZE ADFRT AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEUYN AEVXI AEXOQ AFJKZ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGEKW AGGSO AGUBO AGYEJ AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BENPR BHPHI BKEYQ BKNYI BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CJTIS CNWQP CS3 DWQXO EBS EFJIC EFKBS EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K9- KOM L7B LK8 LUGTX LW9 M0R M0T M1P M29 M2O M41 M7P MO0 N9A NAPCQ O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO Q38 ROL RPZ SAB SCC SDF SDG SDP SES SNL SPCBC SSH SSI SSZ T5K UKHRP UV1 WH7 WOW Z5R ~G- .GJ 29Q 3V. AACTN AAQXK ABWVN ABXDB ACRPL ADMUD ADNMO ADVLN AFCTW AFKWA AGHFR AHHHB AJOXV ALIPV AMFUW ASPBG AVWKF AZFZN EJD FEDTE FGOYB G-2 HEJ HLV HMG HMK HMO HVGLF HX~ HZ~ R2- RIG SAE SEW SIN SVS WUQ XPP ZGI ZXP AAYXX ACMHX ADSLC AGQPQ AGRNS AGWPP CITATION 7QL 7T2 7T5 7U9 7XB 8FK C1K H94 K9. M7N MBDVC PKEHL PQEST PQUKI Q9U 7X8 7S9 L.6 |
| ID | FETCH-LOGICAL-c456t-67ff75d517e881edd537824144f2509d809048a7afea77acf4bb5d890aa108323 |
| IEDL.DBID | BENPR |
| ISSN | 0264-410X 1873-2518 |
| IngestDate | Fri Aug 22 20:40:25 EDT 2025 Fri Jul 11 12:30:49 EDT 2025 Wed Aug 13 04:52:41 EDT 2025 Tue Jul 01 01:07:14 EDT 2025 Thu Apr 24 23:05:15 EDT 2025 Tue Feb 25 19:57:05 EST 2025 Tue Aug 26 16:34:49 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 40 |
| Keywords | Adenovirus-vectored vaccine Variants of concern SARS-CoV-2 Elderly Heterologous COVID-19 vaccine COPD |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c456t-67ff75d517e881edd537824144f2509d809048a7afea77acf4bb5d890aa108323 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-4409-1832 0000-0001-7995-8649 0000-0003-4459-7681 0000-0002-2544-7322 0000-0001-6182-6218 0000-0002-7239-9482 0000-0003-1375-4541 0000-0002-3081-1379 |
| PQID | 2861746987 |
| PQPubID | 105530 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_3200289419 proquest_miscellaneous_2854346513 proquest_journals_2861746987 crossref_citationtrail_10_1016_j_vaccine_2023_08_034 crossref_primary_10_1016_j_vaccine_2023_08_034 elsevier_clinicalkeyesjournals_1_s2_0_S0264410X23009660 elsevier_clinicalkey_doi_10_1016_j_vaccine_2023_08_034 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-09-15 |
| PublicationDateYYYYMMDD | 2023-09-15 |
| PublicationDate_xml | – month: 09 year: 2023 text: 2023-09-15 day: 15 |
| PublicationDecade | 2020 |
| PublicationPlace | Kidlington |
| PublicationPlace_xml | – name: Kidlington |
| PublicationTitle | Vaccine |
| PublicationYear | 2023 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Southworth, Jackson, Singh (b0090) 2022; 60 Gasmi, Peana, Pivina, Srinath, Gasmi Benahmed, Semenova (b0020) 2021; 224 Gram, Nielsen, Schelde, Nielsen, Moustsen-Helms, Sørensen (b0155) 2021; 18 Hotez, Bottazzi (b0100) 2022; 73 Burel, Nath, Pritchard, White, Davies, Towers (b0245) 2012; S4 Schmidt, Klemis, Schub, Mihm, Hielscher, Marx (b0175) 2021; 27 Pérez-Then, Lucas, Monteiro, Miric, Brache, Cochon (b0225) 2022; 28 Muik, Lui, Wallisch, Bacher, Mühl, Reinholz (b0205) 2022; 375 [accessed 1August 2023]. Liu, Shaw, Stuart, Greenland, Aley, Andrews (b0165) 2021; 398 Shokouhi, Hakamifard (b0270) 2021; 19 [accessed 1 August 2023]. Voysey, Clemens, Madhi, Weckx, Folegatti, Aley (b0120) 2021; 397 Maliah, Parikh, Tayer-Shifman, Kimhi, Gepstein, Halperin (b0275) 2022; 12 Chen, Wang, Gilby, Wei (b0200) 2022; 62 Hippisley-Cox, Coupland, Mehta, Keogh, Diaz-Ordaz, Khunti (b0030) 2021; 374 Moss (b0230) 2022; 23 Lacedonia, Scioscia, Santomasi, Fuso, Carpagnano, Portacci (b0025) 2021; 11 Zhu, Zhu (b0250) 2020; 21 Saheb Sharif-Askari, Saheb Sharif-Askari, Alabed, Temsah, Al Heialy, Hamid (b0050) 2020; 18 Watson, Öberg, Angermann, Spalluto, Hühn, Burke (b0070) 2021; 22 Brake, Eapen, McAlinden, Markos, Haug, Larby (b0065) 2022; 17 Hillus, Schwarz, Tober-Lau, Vanshylla, Hastor, Thibeault (b0185) 2021; 9 Cheng, Mok, Leung, Ng, Chan, Ko (b0220) 2022; 28 Young (b0235) 2022; 10 Harboe, Hamm, Pérez-Alós, Sivapalan, Priemé, Wilcke (b0080) 2022; 9 Liwsrisakun, Pata, Laopajon, Takheaw, Chaiwong, Duangjit (b0145) 2023 Chaiwong, Takheaw, Laopajon, Pata, Duangjit, Inchai (b0095) 2022; 10 Graham, Steenbruggen, Miller, Barjaktarevic, Cooper, Hall (b0135) 2019; 200 Tanriover, Doğanay, Akova, Güner, Azap, Akhan (b0110) 2021; 398 Tenbusch, Schumacher, Vogel, Priller, Held, Steininger (b0180) 2021; 21 Borobia, Carcas, Pérez-Olmeda, Castaño, Bertran, García- Pérez (b0160) 2021; 398 Peng, Wang, Chen, Xu, Fang, Sun (b0055) 2022; 322 Pelletier, Desmeules, Lacasse, Tanguay, Milot, Morissette (b0085) 2022; 9 Li, Wang, Sun, Knopf, Herrmann, Lin (b0240) 2022; 29 Ratner, Clark (b0260) 1993; 150 World Health Organization. WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations. World Health Organization; 2021. Wanlapakorn, Suntronwong, Phowatthanasathian, Yorsaeng, Vichaiwattana, Thongmee (b0130) 2022; 18 Rodrigues, Costa de Oliveira (b0060) 2021; 9 Groß, Zanoni, Seidel, Conzelmann, Gilg, Krnavek (b0170) 2022; 75 Halpin, Criner, Papi, Singh, Anzueto, Martinez (b0005) 2021; 203 Knudson, Lebowitz, Holberg, Burrows (b0140) 1983; 127 Nakajima, Nagano, Miyata, Murakami, Mitsuyuki, Funakoshi (b0280) 2022; 18 Zhao, Meng, Kumar, Wu, Huang, Lian (b0035) 2020; 92 Palacios R, Batista AP, Albuquerque CSN, Patiño EG, Santos JP, Conde MTRP, et al. Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study. SSRN. Wu, Hu, Xu, Chen, Yang, Jiang (b0125) 2021; 21 Barros-Martins, Hammerschmidt, Cossmann, Odak, Stankov, Morillas Ramos (b0190) 2021; 27 Zhang, Li, Liang, Li, Liu, Cui (b0210) 2022; 11 Beltramo, Cottenet, Mariet, Georges, Piroth, Tubert-Bitter (b0015) 2021; 58 Higham, Mathioudakis, Vestbo, Singh (b0075) 2020; 29 Lee, Son, Han, Park, Jung (b0045) 2021; 11 Treskova-Schwarzbach, Haas, Reda, Pilic, Borodova, Karimi (b0040) 2021; 19 Liwsrisakun, Pata, Laopajon, Takheaw, Chaiwong, Inchai (b0150) 2022; 19 Ai, Zhang, Zhang, Lin, Zhang, Wu (b0215) 2022; 11 Cohen, Jungsomsri, Sangwongwanich, Tawinprai, Siripongboonsitti, Porntharukchareon (b0195) 2022; 18 Gerayeli, Milne, Cheung, Li, Yang, Tam (b0010) 2021; 33 Kotov, Kotov, Goldberg, Jenkins (b0265) 2018; 200 Topham, Tripp, Doherty (b0255) 1997; 159 Gasmi (10.1016/j.vaccine.2023.08.034_b0020) 2021; 224 Higham (10.1016/j.vaccine.2023.08.034_b0075) 2020; 29 Wanlapakorn (10.1016/j.vaccine.2023.08.034_b0130) 2022; 18 Saheb Sharif-Askari (10.1016/j.vaccine.2023.08.034_b0050) 2020; 18 Brake (10.1016/j.vaccine.2023.08.034_b0065) 2022; 17 Chaiwong (10.1016/j.vaccine.2023.08.034_b0095) 2022; 10 Maliah (10.1016/j.vaccine.2023.08.034_b0275) 2022; 12 10.1016/j.vaccine.2023.08.034_b0115 Burel (10.1016/j.vaccine.2023.08.034_b0245) 2012; S4 Southworth (10.1016/j.vaccine.2023.08.034_b0090) 2022; 60 Moss (10.1016/j.vaccine.2023.08.034_b0230) 2022; 23 Lacedonia (10.1016/j.vaccine.2023.08.034_b0025) 2021; 11 Cohen (10.1016/j.vaccine.2023.08.034_b0195) 2022; 18 Voysey (10.1016/j.vaccine.2023.08.034_b0120) 2021; 397 Cheng (10.1016/j.vaccine.2023.08.034_b0220) 2022; 28 Gram (10.1016/j.vaccine.2023.08.034_b0155) 2021; 18 Watson (10.1016/j.vaccine.2023.08.034_b0070) 2021; 22 Hippisley-Cox (10.1016/j.vaccine.2023.08.034_b0030) 2021; 374 10.1016/j.vaccine.2023.08.034_b0105 Halpin (10.1016/j.vaccine.2023.08.034_b0005) 2021; 203 Young (10.1016/j.vaccine.2023.08.034_b0235) 2022; 10 Treskova-Schwarzbach (10.1016/j.vaccine.2023.08.034_b0040) 2021; 19 Liu (10.1016/j.vaccine.2023.08.034_b0165) 2021; 398 Hotez (10.1016/j.vaccine.2023.08.034_b0100) 2022; 73 Muik (10.1016/j.vaccine.2023.08.034_b0205) 2022; 375 Zhang (10.1016/j.vaccine.2023.08.034_b0210) 2022; 11 Nakajima (10.1016/j.vaccine.2023.08.034_b0280) 2022; 18 Pérez-Then (10.1016/j.vaccine.2023.08.034_b0225) 2022; 28 Shokouhi (10.1016/j.vaccine.2023.08.034_b0270) 2021; 19 Borobia (10.1016/j.vaccine.2023.08.034_b0160) 2021; 398 Wu (10.1016/j.vaccine.2023.08.034_b0125) 2021; 21 Liwsrisakun (10.1016/j.vaccine.2023.08.034_b0150) 2022; 19 Gerayeli (10.1016/j.vaccine.2023.08.034_b0010) 2021; 33 Harboe (10.1016/j.vaccine.2023.08.034_b0080) 2022; 9 Groß (10.1016/j.vaccine.2023.08.034_b0170) 2022; 75 Chen (10.1016/j.vaccine.2023.08.034_b0200) 2022; 62 Ratner (10.1016/j.vaccine.2023.08.034_b0260) 1993; 150 Topham (10.1016/j.vaccine.2023.08.034_b0255) 1997; 159 Kotov (10.1016/j.vaccine.2023.08.034_b0265) 2018; 200 Beltramo (10.1016/j.vaccine.2023.08.034_b0015) 2021; 58 Peng (10.1016/j.vaccine.2023.08.034_b0055) 2022; 322 Barros-Martins (10.1016/j.vaccine.2023.08.034_b0190) 2021; 27 Hillus (10.1016/j.vaccine.2023.08.034_b0185) 2021; 9 Zhu (10.1016/j.vaccine.2023.08.034_b0250) 2020; 21 Schmidt (10.1016/j.vaccine.2023.08.034_b0175) 2021; 27 Graham (10.1016/j.vaccine.2023.08.034_b0135) 2019; 200 Tanriover (10.1016/j.vaccine.2023.08.034_b0110) 2021; 398 Tenbusch (10.1016/j.vaccine.2023.08.034_b0180) 2021; 21 Pelletier (10.1016/j.vaccine.2023.08.034_b0085) 2022; 9 Knudson (10.1016/j.vaccine.2023.08.034_b0140) 1983; 127 Li (10.1016/j.vaccine.2023.08.034_b0240) 2022; 29 Liwsrisakun (10.1016/j.vaccine.2023.08.034_b0145) 2023 Ai (10.1016/j.vaccine.2023.08.034_b0215) 2022; 11 Rodrigues (10.1016/j.vaccine.2023.08.034_b0060) 2021; 9 Zhao (10.1016/j.vaccine.2023.08.034_b0035) 2020; 92 Lee (10.1016/j.vaccine.2023.08.034_b0045) 2021; 11 |
| References_xml | – volume: 73 start-page: 55 year: 2022 end-page: 64 ident: b0100 article-title: Whole inactivated virus and protein-based COVID-19 vaccines publication-title: Annu Rev Med – year: 2023 ident: b0145 article-title: Humoral and cellular immune responses against SARS-CoV-2 variants of concern induced by heterologous CoronaVac/ChAdOx-1 versus homologous ChAdOx-1 vaccination in the elderly publication-title: Asian Pac J Allergy Immunol – volume: 19 start-page: 1 year: 2021 end-page: 2 ident: b0270 article-title: COVID-19 vaccine and corticosteroids: a challenging issue publication-title: Eur J Inflamm – volume: 398 start-page: 856 year: 2021 end-page: 869 ident: b0165 article-title: Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial publication-title: Lancet – volume: 398 start-page: 121 year: 2021 end-page: 130 ident: b0160 article-title: Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial publication-title: Lancet – volume: 11 start-page: 1 year: 2022 end-page: 5 ident: b0210 article-title: The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron publication-title: Emerg Microbes Infect – volume: 19 year: 2022 ident: b0150 article-title: Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine publication-title: Immun Ageing – volume: 27 start-page: 1530 year: 2021 end-page: 1535 ident: b0175 article-title: Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination publication-title: Nat Med – volume: 58 year: 2021 ident: b0015 article-title: Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: a nationwide study publication-title: Eur Respir J – volume: 159 start-page: 5197 year: 1997 end-page: 5200 ident: b0255 article-title: CD8+ T cells clear influenza virus by perforin or Fas-dependent processes publication-title: J Immunol – volume: 9 year: 2022 ident: b0080 article-title: Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases publication-title: BMJ Open Respir Res – volume: 60 year: 2022 ident: b0090 article-title: Airway immune responses to COVID-19 vaccination in COPD patients and healthy subjects publication-title: Eur Respir J – volume: 27 start-page: 1525 year: 2021 end-page: 1529 ident: b0190 article-title: Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination publication-title: Nat Med – volume: 18 year: 2022 ident: b0195 article-title: Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines publication-title: Hum Vaccin Immunother – volume: 12 year: 2022 ident: b0275 article-title: Steroid treatment suppresses the CD4+ T-cell response to the third dose of mRNA COVID-19 vaccine in systemic autoimmune rheumatic disease patients publication-title: Sci Rep – volume: 200 start-page: e70 year: 2019 end-page: e88 ident: b0135 article-title: Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement publication-title: Am J Respir Crit Care Med – volume: 18 year: 2021 ident: b0155 article-title: Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: a nationwide population-based cohort study publication-title: PLoS Med – volume: 28 start-page: 481 year: 2022 end-page: 485 ident: b0225 article-title: Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination publication-title: Nat Med – volume: 29 start-page: 1107 year: 2022 end-page: 1122 ident: b0240 article-title: Immune response in COVID-19: what is next? publication-title: Cell Death Differ – volume: 9 year: 2021 ident: b0060 article-title: The impact of angiotensin-converting enzyme 2 (ACE2) expression levels in patients with comorbidities on COVID-19 severity: a comprehensive review publication-title: Microorganisms – volume: 23 start-page: 186 year: 2022 end-page: 193 ident: b0230 article-title: The T cell immune response against SARS-CoV-2 publication-title: Nat Immunol – volume: 374 year: 2021 ident: b0030 article-title: Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study publication-title: BMJ – volume: 17 start-page: 101 year: 2022 end-page: 115 ident: b0065 article-title: SARS-CoV-2 (COVID-19) adhesion site protein upregulation in small airways, type 2 pneumocytes, and alveolar macrophages of smokers and COPD-possible implications for interstitial fibrosis publication-title: Int J Chron Obstruct Pulmon Dis – volume: 9 start-page: 591 year: 2022 end-page: 595 ident: b0085 article-title: Antibody response to severe acute respiratory syndrome coronavirus-2 vaccination in COPD: a cohort study publication-title: Chronic Obstr Pulm Dis – volume: 75 year: 2022 ident: b0170 article-title: Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants publication-title: EBioMedicine – reference: [accessed 1 August 2023]. – volume: 92 start-page: 1915 year: 2020 end-page: 1921 ident: b0035 article-title: The impact of COPD and smoking history on the severity of COVID-19: a systemic review and meta- analysis publication-title: J Med Virol – volume: 21 start-page: 1212 year: 2021 end-page: 1213 ident: b0180 article-title: Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 publication-title: Lancet Infect Dis – volume: 10 year: 2022 ident: b0095 article-title: Neutralizing antibody and T-cell responses against SARS-CoV-2 wild-type and variants of concern in chronic obstructive pulmonary disease subjects after ChAdOx-1/ChAdOx-1 homologous vaccination: a preliminary study publication-title: Vaccines (Basel) – volume: 62 start-page: 412 year: 2022 end-page: 422 ident: b0200 article-title: Omicron variant (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance publication-title: J Chem Inf Model – volume: 11 year: 2021 ident: b0045 article-title: Impact of COPD on COVID-19 prognosis: a nationwide population-based study in South Korea publication-title: Sci Rep – volume: 203 start-page: 24 year: 2021 end-page: 36 ident: b0005 article-title: Global initiative for the diagnosis, management, and prevention of chronic obstructive lung disease. The 2020 GOLD Science Committee report on COVID-19 and chronic obstructive pulmonary disease publication-title: Am J Respir Crit Care Med – volume: 397 start-page: 99 year: 2021 end-page: 111 ident: b0120 article-title: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK publication-title: Lancet – volume: 33 year: 2021 ident: b0010 article-title: COPD and the risk of poor outcomes in COVID-19: a systematic review and meta-analysis publication-title: EClinicalMedicine – volume: 224 year: 2021 ident: b0020 article-title: Interrelations between COVID-19 and other disorders publication-title: Clin Immunol – volume: 375 start-page: 678 year: 2022 end-page: 680 ident: b0205 article-title: Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera publication-title: Science – volume: 150 start-page: 4303 year: 1993 end-page: 4314 ident: b0260 article-title: Role of TNF-alpha in CD8+ cytotoxic T lymphocyte-mediated lysis publication-title: J Immunol – volume: 398 start-page: 213 year: 2021 end-page: 222 ident: b0110 article-title: Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey publication-title: Lancet – volume: 18 year: 2022 ident: b0130 article-title: Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study publication-title: Hum Vaccin Immunother – volume: 11 year: 2021 ident: b0025 article-title: Impact of smoking, COPD and comorbidities on the mortality of COVID-19 patients publication-title: Sci Rep – volume: 18 start-page: 1 year: 2020 end-page: 6 ident: b0050 article-title: Airways expression of SARS-CoV-2 receptor, ACE2, and TMPRSS2 is lower in children than adults and increases with smoking and COPD publication-title: Mol Ther Methods Clin Dev – volume: 10 year: 2022 ident: b0235 article-title: T cells in SARS-CoV-2 infection and vaccination publication-title: Ther Adv Vaccines Immunother – volume: 322 start-page: L712 year: 2022 end-page: L721 ident: b0055 article-title: Angiotensin-converting enzyme 2 in peripheral lung club cells modulates the susceptibility to SARS-CoV-2 in chronic obstructive pulmonary disease publication-title: Am J Physiol Lung Cell Mol Physiol – volume: 9 start-page: 1255 year: 2021 end-page: 1265 ident: b0185 article-title: Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study publication-title: Lancet Respir Med – volume: S4 year: 2012 ident: b0245 article-title: Evaluation of immune responses to influenza vaccination in chronic obstructive pulmonary disease publication-title: J Vaccines Vaccine – reference: [accessed 1August 2023]. – volume: 127 start-page: 725 year: 1983 end-page: 734 ident: b0140 article-title: Changes in the normal maximal expiratory flow-volume curve with growth and aging publication-title: Am Rev Respir Dis – volume: 21 year: 2020 ident: b0250 article-title: CD4 T helper cell subsets and related human immunological disorders publication-title: Int J Mol Sci – volume: 22 year: 2021 ident: b0070 article-title: Dysregulation of COVID-19 related gene expression in the COPD lung publication-title: Respir Res – volume: 29 year: 2020 ident: b0075 article-title: COVID-19 and COPD: a narrative review of the basic science and clinical outcomes publication-title: Eur Respir Rev – volume: 11 start-page: 337 year: 2022 end-page: 343 ident: b0215 article-title: Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost publication-title: Emerg Microbes Infect – reference: Palacios R, Batista AP, Albuquerque CSN, Patiño EG, Santos JP, Conde MTRP, et al. Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study. SSRN. – volume: 21 start-page: 803 year: 2021 end-page: 812 ident: b0125 article-title: Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial publication-title: Lancet Infect Dis – volume: 200 start-page: 2004 year: 2018 end-page: 2012 ident: b0265 article-title: Many Th cell subsets have fas ligand-dependent cytotoxic potential publication-title: J Immunol – reference: World Health Organization. WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations. World Health Organization; 2021. – volume: 18 year: 2022 ident: b0280 article-title: Inhaled corticosteroids do not affect the antibody titer against the SARS-CoV-2 spike protein in BNT162b2 mRNA vaccinated patients publication-title: Allergy Asthma Clin Immunol – volume: 19 year: 2021 ident: b0040 article-title: Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence publication-title: BMC Med – volume: 28 start-page: 486 year: 2022 end-page: 489 ident: b0220 article-title: Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination publication-title: Nat Med – volume: 9 issue: 8 year: 2021 ident: 10.1016/j.vaccine.2023.08.034_b0060 article-title: The impact of angiotensin-converting enzyme 2 (ACE2) expression levels in patients with comorbidities on COVID-19 severity: a comprehensive review publication-title: Microorganisms doi: 10.3390/microorganisms9081692 – volume: 10 issue: 12 year: 2022 ident: 10.1016/j.vaccine.2023.08.034_b0095 article-title: Neutralizing antibody and T-cell responses against SARS-CoV-2 wild-type and variants of concern in chronic obstructive pulmonary disease subjects after ChAdOx-1/ChAdOx-1 homologous vaccination: a preliminary study publication-title: Vaccines (Basel) – volume: 200 start-page: 2004 issue: 6 year: 2018 ident: 10.1016/j.vaccine.2023.08.034_b0265 article-title: Many Th cell subsets have fas ligand-dependent cytotoxic potential publication-title: J Immunol doi: 10.4049/jimmunol.1700420 – volume: 92 start-page: 1915 issue: 10 year: 2020 ident: 10.1016/j.vaccine.2023.08.034_b0035 article-title: The impact of COPD and smoking history on the severity of COVID-19: a systemic review and meta- analysis publication-title: J Med Virol doi: 10.1002/jmv.25889 – volume: 398 start-page: 121 issue: 10295 year: 2021 ident: 10.1016/j.vaccine.2023.08.034_b0160 article-title: Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial publication-title: Lancet doi: 10.1016/S0140-6736(21)01420-3 – volume: 58 issue: 6 year: 2021 ident: 10.1016/j.vaccine.2023.08.034_b0015 article-title: Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: a nationwide study publication-title: Eur Respir J doi: 10.1183/13993003.04474-2020 – volume: 21 start-page: 1212 issue: 9 year: 2021 ident: 10.1016/j.vaccine.2023.08.034_b0180 article-title: Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(21)00420-5 – volume: 27 start-page: 1525 issue: 9 year: 2021 ident: 10.1016/j.vaccine.2023.08.034_b0190 article-title: Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination publication-title: Nat Med doi: 10.1038/s41591-021-01449-9 – volume: 127 start-page: 725 year: 1983 ident: 10.1016/j.vaccine.2023.08.034_b0140 article-title: Changes in the normal maximal expiratory flow-volume curve with growth and aging publication-title: Am Rev Respir Dis – volume: 19 start-page: 1 year: 2021 ident: 10.1016/j.vaccine.2023.08.034_b0270 article-title: COVID-19 vaccine and corticosteroids: a challenging issue publication-title: Eur J Inflamm doi: 10.1177/20587392211066188 – volume: 375 start-page: 678 issue: 6581 year: 2022 ident: 10.1016/j.vaccine.2023.08.034_b0205 article-title: Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera publication-title: Science doi: 10.1126/science.abn7591 – volume: 11 issue: 1 year: 2021 ident: 10.1016/j.vaccine.2023.08.034_b0025 article-title: Impact of smoking, COPD and comorbidities on the mortality of COVID-19 patients publication-title: Sci Rep doi: 10.1038/s41598-021-98749-4 – ident: 10.1016/j.vaccine.2023.08.034_b0105 – volume: 18 issue: 1 year: 2022 ident: 10.1016/j.vaccine.2023.08.034_b0130 article-title: Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study publication-title: Hum Vaccin Immunother doi: 10.1080/21645515.2022.2029111 – volume: 200 start-page: e70 issue: 8 year: 2019 ident: 10.1016/j.vaccine.2023.08.034_b0135 article-title: Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201908-1590ST – volume: 150 start-page: 4303 issue: 10 year: 1993 ident: 10.1016/j.vaccine.2023.08.034_b0260 article-title: Role of TNF-alpha in CD8+ cytotoxic T lymphocyte-mediated lysis publication-title: J Immunol doi: 10.4049/jimmunol.150.10.4303 – volume: 397 start-page: 99 issue: 10269 year: 2021 ident: 10.1016/j.vaccine.2023.08.034_b0120 article-title: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK publication-title: Lancet doi: 10.1016/S0140-6736(20)32661-1 – volume: 21 issue: 21 year: 2020 ident: 10.1016/j.vaccine.2023.08.034_b0250 article-title: CD4 T helper cell subsets and related human immunological disorders publication-title: Int J Mol Sci doi: 10.3390/ijms21218011 – volume: 17 start-page: 101 year: 2022 ident: 10.1016/j.vaccine.2023.08.034_b0065 article-title: SARS-CoV-2 (COVID-19) adhesion site protein upregulation in small airways, type 2 pneumocytes, and alveolar macrophages of smokers and COPD-possible implications for interstitial fibrosis publication-title: Int J Chron Obstruct Pulmon Dis doi: 10.2147/COPD.S329783 – volume: 322 start-page: L712 issue: 5 year: 2022 ident: 10.1016/j.vaccine.2023.08.034_b0055 article-title: Angiotensin-converting enzyme 2 in peripheral lung club cells modulates the susceptibility to SARS-CoV-2 in chronic obstructive pulmonary disease publication-title: Am J Physiol Lung Cell Mol Physiol doi: 10.1152/ajplung.00305.2021 – volume: 9 issue: 1 year: 2022 ident: 10.1016/j.vaccine.2023.08.034_b0080 article-title: Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases publication-title: BMJ Open Respir Res doi: 10.1136/bmjresp-2022-001268 – volume: 398 start-page: 213 issue: 10296 year: 2021 ident: 10.1016/j.vaccine.2023.08.034_b0110 article-title: Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey publication-title: Lancet doi: 10.1016/S0140-6736(21)01429-X – volume: 10 year: 2022 ident: 10.1016/j.vaccine.2023.08.034_b0235 article-title: T cells in SARS-CoV-2 infection and vaccination publication-title: Ther Adv Vaccines Immunother – volume: 12 issue: 1 year: 2022 ident: 10.1016/j.vaccine.2023.08.034_b0275 article-title: Steroid treatment suppresses the CD4+ T-cell response to the third dose of mRNA COVID-19 vaccine in systemic autoimmune rheumatic disease patients publication-title: Sci Rep doi: 10.1038/s41598-022-25642-z – volume: 73 start-page: 55 year: 2022 ident: 10.1016/j.vaccine.2023.08.034_b0100 article-title: Whole inactivated virus and protein-based COVID-19 vaccines publication-title: Annu Rev Med doi: 10.1146/annurev-med-042420-113212 – volume: 374 year: 2021 ident: 10.1016/j.vaccine.2023.08.034_b0030 article-title: Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study publication-title: BMJ – year: 2023 ident: 10.1016/j.vaccine.2023.08.034_b0145 article-title: Humoral and cellular immune responses against SARS-CoV-2 variants of concern induced by heterologous CoronaVac/ChAdOx-1 versus homologous ChAdOx-1 vaccination in the elderly publication-title: Asian Pac J Allergy Immunol – volume: 398 start-page: 856 issue: 10303 year: 2021 ident: 10.1016/j.vaccine.2023.08.034_b0165 article-title: Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial publication-title: Lancet doi: 10.1016/S0140-6736(21)01694-9 – volume: 11 issue: 1 year: 2021 ident: 10.1016/j.vaccine.2023.08.034_b0045 article-title: Impact of COPD on COVID-19 prognosis: a nationwide population-based study in South Korea publication-title: Sci Rep – volume: 28 start-page: 486 issue: 3 year: 2022 ident: 10.1016/j.vaccine.2023.08.034_b0220 article-title: Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination publication-title: Nat Med doi: 10.1038/s41591-022-01704-7 – volume: 19 issue: 1 year: 2021 ident: 10.1016/j.vaccine.2023.08.034_b0040 article-title: Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence publication-title: BMC Med doi: 10.1186/s12916-021-02058-6 – volume: 23 start-page: 186 issue: 2 year: 2022 ident: 10.1016/j.vaccine.2023.08.034_b0230 article-title: The T cell immune response against SARS-CoV-2 publication-title: Nat Immunol doi: 10.1038/s41590-021-01122-w – volume: 11 start-page: 337 issue: 1 year: 2022 ident: 10.1016/j.vaccine.2023.08.034_b0215 article-title: Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost publication-title: Emerg Microbes Infect doi: 10.1080/22221751.2021.2022440 – volume: 29 start-page: 1107 issue: 6 year: 2022 ident: 10.1016/j.vaccine.2023.08.034_b0240 article-title: Immune response in COVID-19: what is next? publication-title: Cell Death Differ doi: 10.1038/s41418-022-01015-x – volume: 18 start-page: 1 year: 2020 ident: 10.1016/j.vaccine.2023.08.034_b0050 article-title: Airways expression of SARS-CoV-2 receptor, ACE2, and TMPRSS2 is lower in children than adults and increases with smoking and COPD publication-title: Mol Ther Methods Clin Dev doi: 10.1016/j.omtm.2020.05.013 – volume: 9 start-page: 1255 issue: 11 year: 2021 ident: 10.1016/j.vaccine.2023.08.034_b0185 article-title: Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(21)00357-X – volume: 9 start-page: 591 issue: 4 year: 2022 ident: 10.1016/j.vaccine.2023.08.034_b0085 article-title: Antibody response to severe acute respiratory syndrome coronavirus-2 vaccination in COPD: a cohort study publication-title: Chronic Obstr Pulm Dis – volume: 28 start-page: 481 issue: 3 year: 2022 ident: 10.1016/j.vaccine.2023.08.034_b0225 article-title: Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination publication-title: Nat Med doi: 10.1038/s41591-022-01705-6 – volume: 224 year: 2021 ident: 10.1016/j.vaccine.2023.08.034_b0020 article-title: Interrelations between COVID-19 and other disorders publication-title: Clin Immunol doi: 10.1016/j.clim.2020.108651 – volume: 62 start-page: 412 issue: 2 year: 2022 ident: 10.1016/j.vaccine.2023.08.034_b0200 article-title: Omicron variant (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance publication-title: J Chem Inf Model doi: 10.1021/acs.jcim.1c01451 – volume: 22 issue: 1 year: 2021 ident: 10.1016/j.vaccine.2023.08.034_b0070 article-title: Dysregulation of COVID-19 related gene expression in the COPD lung publication-title: Respir Res doi: 10.1186/s12931-021-01755-3 – volume: 18 issue: 5 year: 2022 ident: 10.1016/j.vaccine.2023.08.034_b0195 article-title: Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines publication-title: Hum Vaccin Immunother doi: 10.1080/21645515.2022.2052525 – volume: 11 start-page: 1 issue: 1 year: 2022 ident: 10.1016/j.vaccine.2023.08.034_b0210 article-title: The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron publication-title: Emerg Microbes Infect doi: 10.1080/22221751.2021.2017757 – volume: 29 issue: 158 year: 2020 ident: 10.1016/j.vaccine.2023.08.034_b0075 article-title: COVID-19 and COPD: a narrative review of the basic science and clinical outcomes publication-title: Eur Respir Rev doi: 10.1183/16000617.0199-2020 – volume: 33 year: 2021 ident: 10.1016/j.vaccine.2023.08.034_b0010 article-title: COPD and the risk of poor outcomes in COVID-19: a systematic review and meta-analysis publication-title: EClinicalMedicine doi: 10.1016/j.eclinm.2021.100789 – ident: 10.1016/j.vaccine.2023.08.034_b0115 – volume: 75 year: 2022 ident: 10.1016/j.vaccine.2023.08.034_b0170 article-title: Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants publication-title: EBioMedicine doi: 10.1016/j.ebiom.2021.103761 – volume: S4 year: 2012 ident: 10.1016/j.vaccine.2023.08.034_b0245 article-title: Evaluation of immune responses to influenza vaccination in chronic obstructive pulmonary disease publication-title: J Vaccines Vaccine – volume: 159 start-page: 5197 issue: 11 year: 1997 ident: 10.1016/j.vaccine.2023.08.034_b0255 article-title: CD8+ T cells clear influenza virus by perforin or Fas-dependent processes publication-title: J Immunol doi: 10.4049/jimmunol.159.11.5197 – volume: 60 year: 2022 ident: 10.1016/j.vaccine.2023.08.034_b0090 article-title: Airway immune responses to COVID-19 vaccination in COPD patients and healthy subjects publication-title: Eur Respir J doi: 10.1183/13993003.00497-2022 – volume: 203 start-page: 24 issue: 1 year: 2021 ident: 10.1016/j.vaccine.2023.08.034_b0005 article-title: Global initiative for the diagnosis, management, and prevention of chronic obstructive lung disease. The 2020 GOLD Science Committee report on COVID-19 and chronic obstructive pulmonary disease publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.202009-3533SO – volume: 18 issue: 12 year: 2021 ident: 10.1016/j.vaccine.2023.08.034_b0155 article-title: Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: a nationwide population-based cohort study publication-title: PLoS Med doi: 10.1371/journal.pmed.1003874 – volume: 19 issue: 1 year: 2022 ident: 10.1016/j.vaccine.2023.08.034_b0150 article-title: Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine publication-title: Immun Ageing doi: 10.1186/s12979-022-00279-8 – volume: 21 start-page: 803 issue: 6 year: 2021 ident: 10.1016/j.vaccine.2023.08.034_b0125 article-title: Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(20)30987-7 – volume: 27 start-page: 1530 issue: 9 year: 2021 ident: 10.1016/j.vaccine.2023.08.034_b0175 article-title: Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination publication-title: Nat Med doi: 10.1038/s41591-021-01464-w – volume: 18 issue: 1 year: 2022 ident: 10.1016/j.vaccine.2023.08.034_b0280 article-title: Inhaled corticosteroids do not affect the antibody titer against the SARS-CoV-2 spike protein in BNT162b2 mRNA vaccinated patients publication-title: Allergy Asthma Clin Immunol doi: 10.1186/s13223-022-00719-6 |
| SSID | ssj0005319 |
| Score | 2.418613 |
| Snippet | Data on humoral and cellular immune responses against SARS-CoV-2 after receiving heterologous CoronaVac/ChAdOx-1 (CoVac/ChAd) vaccination in subjects with... AbstractBackgroundData on humoral and cellular immune responses against SARS-CoV-2 after receiving heterologous CoronaVac/ChAdOx-1 (CoVac/ChAd) vaccination in... BackgroundData on humoral and cellular immune responses against SARS-CoV-2 after receiving heterologous CoronaVac/ChAdOx-1 (CoVac/ChAd) vaccination in subjects... |
| SourceID | proquest crossref elsevier |
| SourceType | Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 5901 |
| SubjectTerms | Adenovirus-vectored vaccine Allergy and Immunology Antibodies CD4 antigen CD4-positive T-lymphocytes CD8 antigen CD8-positive T-lymphocytes Chronic obstructive pulmonary disease Clinical trials COPD COVID-19 COVID-19 vaccines Disease transmission Elderly FasL protein Health care Heterologous COVID-19 vaccine Immune response (cell-mediated) Immune response (humoral) Interleukin 10 Interleukin 17 Interleukin 4 Lung diseases Lymphocytes T Neutralizing Normal distribution Obstructive lung disease Older people Pandemics Peptides Proteins respiratory tract diseases SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Tumor necrosis factor-α vaccination Vaccines Variants of concern γ-Interferon |
| Title | Neutralizing antibody and T-cell responses against SARS-CoV-2 variants by heterologous CoronaVac/ChAdOx-1 vaccination in elderly subjects with chronic obstructive pulmonary disease |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0264410X23009660 https://www.clinicalkey.es/playcontent/1-s2.0-S0264410X23009660 https://www.proquest.com/docview/2861746987 https://www.proquest.com/docview/2854346513 https://www.proquest.com/docview/3200289419 |
| Volume | 41 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3fb9MwELZYJxAvCAqIwkBGQnua26SxY-cJlWrThLRSrV3VN8uxHdapagtZK8oDfxV_IHf50UqIsZcoUnxJG1_uPp_v7iPkA1eJcDLKWGZjxXimIpYECQI58D5WBsoLrEa-GMTnV_zzVEyrgFtepVXWNrEw1G5pMUbe6SrwtUh3KD-uvjFkjcLd1YpC44AcgglWokEOP50Ohpf7JI-ooPaAhQZnPAym-xqezk17YyxuXreRQbzo4xnxu7zTX3a6cD5nT8mTCjXSXjnNz8gDv2iShyWP5LZJHl1UO-RNcjwse1FvT-h4X1qVn9BjOtx3qQaZ5gQTYYpqXFqLPye_BzAeYx8_waVReOuzdOm2cOLomGGQn34vk2p9Ts1XMwNwSUe9yxHrLyesSzew8sbEGppu6TXeHx-2XOe0j40SzMTYTv-65778YCEt30uhGHS2oB7pwudbmq9TDA3lFCPE1Ja9e-kyrRrdbjxdrecwGfi7q92lF-Tq7HTcP2cVsQOzgNduWSyzTAonQumVCr1zIgKgwmFtlwEiS5wKEjAsRprMGymNzXiaCqeSwJgQIGM3ekkai-XCvyLUJlhblKWRiy13IlNCWZtwwMEmAKmwRXg9odpWXc-RfGOu6_S2G13pgUY90EjKGfEWae_EVmXbj_sE4lpbdF3TClZYg2O6T1D-S9DnlS3Jdajzrg70KCiwazCFRWOAPVVb5KjWSr0bvP9MWuT97jKYDFQRs_Aw5RqLZiMeizC6e0zULfageZi8_v9j3pDH-G8whSYUR6QByuDfAk67Td-Rg_avEI5yKuGo-nBefp5_AMV6QpQ |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bbxJBFJ40bby8GEWNaNUx0T51YC-ztwdjENtQW5AUSngbZ2dmLQ0BdAu6_iif_IGesxdIjLVPfSNhDgucb875Zs6NkNc8jDwduAlLlB8ynoQui6wIiRx4HxVYofGwGrnb8ztn_OPYG2-RX1UtDKZVVjYxN9R6rvCOvOmE4Gtx3GHwbvGV4dQojK5WIzQKWByb7Dsc2dK3Rx9Av28c5_Bg2O6wcqoAU0AWLpkfJEngac8OTBjaRmvPBS_J4WCRAB2IdGhFgGoZyMTIIJAq4XHs6TCypLSBr2CjAzD5O0AzIthFO-8Pev3TTVKJm48SgYMNZ9y2xpuaoeZFYyUVBssbOLE87xvq8qu84V9-IXd2h_fJvZKl0lYBqwdky8xq5FYxtzKrkdvdMiJfI3v9ovd1tk-Hm1KudJ_u0f6mKzbI1EaYeJNX_9JK_CH53YP1eNfyE1woBS1P4rnO4IWmQ4ZBBfqtSOI1KZVf5ATILB20TgesPR8xh67gpI-JPDTO6Dl-Pj5svkxpGxszyJFUzfZ5S3_6wWxa_C85EOlkRg2OJ59mNF3GeBWVUryRpqroFUzncdlYd2XoYjkF5eP3LqNZj8jZjaj8MdmezWfmCaEqwlqmJHa1r7j2ktALlYo48G5pgZRdJ7xSqFBll3Uc9jEVVTrdhShxIBAHAoeAurxOGmuxRdFm5DoBv0KLqGpoweoLcITXCQb_EjRpabtSYYvUEZYYWDlXtsZwSLWwh2ud7FaoFOvFm21ZJ6_Wb4OJQojImQGVCyzSdbnv2e7Va1wnj3lzO3r6_8e8JHc6w-6JODnqHT8jd_GXYfqO7e2SbQCGeQ4c8TJ-UW5MSj7ftC34A-CQe_0 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF5Vqai4IAggAgUWCXqqEz_W9vqAUEgbtZSGqEmj3Jb17pqmiuKAm0D4XZz4dcz4kUiI0lNvkbxjJ5nxfLM7M98Q8prxyNehl1iJCrjFEu5ZkR1hIAfoo0KbGx-7kU97wdE5-zD2x1vkd9ULg2WVlU_MHbVOFZ6Rt1wOWIvjDsNWUpZF9A-67-ZfLZwghZnWapxGYSInZvUdtm_Z2-MD0PUb1-0eDjtHVjlhwFIQOFxZQZgkoa99JzScO0Zr3wPEZLDJSCA0iDS3I7BwGcrEyDCUKmFx7Gse2VI6ELsg6QG4_-0QUJHXyPb7w17_bFNg4uVjRWCTwyzm2ONN_1DrsrmUChPnTZxennOIeuw6ZPwLI3Lg694n98qIlbYLE3tAtsysTu4UMyxXdbJzWmbn62SvX_Bgr_bpcNPWle3TPdrfMGSDTH2ERTh5JzCtxB-SXz1Yj-cuPwFOKWh8Eqd6BR80HVqYYKDfioJek1H5RU4gsKWD9tnA6qQjy6VL2PVjUQ-NV_QC748PSxcZ7SBJgxxJ1epctPWnH5ZDi_8lN0o6mVGDo8qnK5otYjyWyiieTlNV8AbTNC5JdpeGzhdTUD5-7zKz9Yic34rKH5PaLJ2ZJ4SqCPuaktjTgWLaT7jPlYoYxODSBimnQVilUKFKxnUc_DEVVWndpSjtQKAdCBwI6rEGaa7F5gXlyE0CQWUtouqnBQQQAIo3CYb_EjRZ6ccy4YjMFbYY2HncbI9hw2ojn2uD7FZWKdaLN69og7xaXwZ3hSYiZwZULrBh12OB73jXr_HcPP_NnOjp_x_zkuyADxAfj3snz8hd_GFYyeP4u6QGdmGeQ7h4Fb8o30tKPt-2K_gDY8OAKQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Neutralizing+antibody+and+T-cell+responses+against+SARS-CoV-2+variants+by+heterologous+CoronaVac%2FChAdOx-1+vaccination+in+elderly+subjects+with+chronic+obstructive+pulmonary+disease&rft.jtitle=Vaccine&rft.au=Chaiwong%2C+Warawut&rft.au=Takheaw%2C+Nuchjira&rft.au=Pata%2C+Supansa&rft.au=Laopajon%2C+Witida&rft.date=2023-09-15&rft.issn=1873-2518&rft.eissn=1873-2518&rft.volume=41&rft.issue=40&rft.spage=5901&rft_id=info:doi/10.1016%2Fj.vaccine.2023.08.034&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0264-410X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0264-410X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0264-410X&client=summon |